RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostasis in Mouse PDAC Cells

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3,...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 826617
Main Authors Mijit, Mahmut, Wireman, Randall, Armstrong, Lee, Gampala, Silpa, Hassan, Zonera, Schneeweis, Christian, Schneider, Guenter, Zhang, Chi, Fishel, Melissa L., Kelley, Mark R.
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered Kras G12D -driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the Kras G12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance.
AbstractList Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered Kras G12D -driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the Kras G12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered Kras G12D-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the Kras G12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance.Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered Kras G12D-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the Kras G12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered -driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the genotype and provide novel therapeutic strategies to combat PDAC drug resistance.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered KrasG12D-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the KrasG12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance.
Author Mijit, Mahmut
Gampala, Silpa
Kelley, Mark R.
Wireman, Randall
Zhang, Chi
Schneeweis, Christian
Schneider, Guenter
Fishel, Melissa L.
Armstrong, Lee
Hassan, Zonera
AuthorAffiliation 7 Department of Pharmacology and Toxicology, Indiana University School of Medicine , Indianapolis, IN , United States
8 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, IN , United States
1 Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine , Indianapolis, IN , United States
2 Department of Clinic and Polyclinic for Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich , Munich , Germany
3 Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen , Göttingen , Germany
4 Department of Medical and Molecular Genetics, Indiana University School of Medicine , Indianapolis, IN , United States
5 Department of Biohealth Informatics, Indiana University-Purdue University (IUPUI) , Indianapolis, IN , United States
9 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University , Indianapolis, IN , United Sta
AuthorAffiliation_xml – name: 4 Department of Medical and Molecular Genetics, Indiana University School of Medicine , Indianapolis, IN , United States
– name: 8 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, IN , United States
– name: 9 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University , Indianapolis, IN , United States
– name: 1 Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine , Indianapolis, IN , United States
– name: 7 Department of Pharmacology and Toxicology, Indiana University School of Medicine , Indianapolis, IN , United States
– name: 6 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine , Indianapolis, IN , United States
– name: 3 Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen , Göttingen , Germany
– name: 5 Department of Biohealth Informatics, Indiana University-Purdue University (IUPUI) , Indianapolis, IN , United States
– name: 2 Department of Clinic and Polyclinic for Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich , Munich , Germany
Author_xml – sequence: 1
  givenname: Mahmut
  surname: Mijit
  fullname: Mijit, Mahmut
– sequence: 2
  givenname: Randall
  surname: Wireman
  fullname: Wireman, Randall
– sequence: 3
  givenname: Lee
  surname: Armstrong
  fullname: Armstrong, Lee
– sequence: 4
  givenname: Silpa
  surname: Gampala
  fullname: Gampala, Silpa
– sequence: 5
  givenname: Zonera
  surname: Hassan
  fullname: Hassan, Zonera
– sequence: 6
  givenname: Christian
  surname: Schneeweis
  fullname: Schneeweis, Christian
– sequence: 7
  givenname: Guenter
  surname: Schneider
  fullname: Schneider, Guenter
– sequence: 8
  givenname: Chi
  surname: Zhang
  fullname: Zhang, Chi
– sequence: 9
  givenname: Melissa L.
  surname: Fishel
  fullname: Fishel, Melissa L.
– sequence: 10
  givenname: Mark R.
  surname: Kelley
  fullname: Kelley, Mark R.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35402225$$D View this record in MEDLINE/PubMed
BookMark eNp1UstuEzEUHaEiWkr3rJCXbJKOHzPxbJCiNNBIBapQJHbWHftO4mpiB9tB8GH8H56kVCkS9sL29XlYx_dlceK8w6J4Tcsx57K57LzTY1YyNpasrunkWXHGGBejRvBvJ0f70-Iixvsyj7oqaclfFKe8EpnHqrPi9xL7KVlEAo7MY0SXLPTkDsIKE-l8IHO3BqetW5EZ9v2uh0CWGLfeRYwkeZLWSK4-TXNxCzZcLrEb0Xww_if5YlcO-oF6G3xC67KJGdjJh30VQ9qFFhKaY_GBeu036GOCaCPJvI9-F5HcXk1ne2B8VTzvoI948bCeF1_fz-9m16Obzx8Ws-nNSIuapZEuDa2BUo2iqicCKglUoikNIMqWV8wwwbATDTZS1poKyFMAl2zSsq5Gfl4sDrrGw73aBruB8Et5sGpf8GGlICSre1SN1G3JjOZGcsEmdLBoeDWBqu2qxrCs9e6gtd21GzQ6Rx2gfyL69MbZtVr5H0rmx1HeZIG3DwLBf9_lFNXGRp3jAIc5H8Vq0bCqZg3P0DfHXo8mf_89A8oDQAcfY8DuEUJLNXSXGrpLDd2lDt2VKfU_FG0TJOuH19r-_8Q_YxfWyw
CitedBy_id crossref_primary_10_1016_j_compbiomed_2024_109395
crossref_primary_10_3390_ijms24021101
crossref_primary_10_1590_1414_431x2024e13250
crossref_primary_10_3389_fmed_2023_1146115
crossref_primary_10_1002_mc_23512
crossref_primary_10_3390_ijms24043251
Cites_doi 10.1186/s13046-021-02046-x
10.1128/MCB.24.17.7806-7819.2004
10.3390/ijms221910279
10.1074/jbc.M114.621995
10.1016/j.drudis.2020.10.015
10.1002/1878-0261.12138
10.1093/ibd/izaa161
10.1007/s00018-010-0488-2
10.1038/s41416-021-01270-8
10.1186/s13046-020-01686-9
10.3390/ijms19123890
10.18632/oncotarget.23493
10.1038/srep29389
10.1021/jm201537d
10.1371/journal.pone.0070909
10.1172/JCI86477
10.1172/JCI29882
10.3390/cancers13184510
10.2174/1874467211205010036
10.1124/jpet.118.248088
10.1038/s41392-021-00641-0
10.1073/pnas.1703096114
10.3389/fcell.2021.731588
10.1021/bi400179m
10.1016/j.cytogfr.2009.11.005
10.1016/j.stem.2018.10.013
10.1038/s41401-020-00584-2
10.1158/1078-0432.CCR-13-1664
10.1038/s41467-021-21736-w
10.1016/j.ccr.2011.12.006
10.1089/107999099313866
10.33696/Signaling.2.044
10.1111/jcmm.16132
10.1158/1535-7163.MCT-18-1166
10.1158/1078-0432.CCR-08-1539
10.1002/ijc.27916
10.1089/ars.2010.3410
10.1089/ars.2008.2120
10.4251/wjgo.v12.i2.173
10.1039/9781839162541-00286
10.1093/nar/gkn416
10.18632/oncotarget.23897
10.18060/22794
10.1021/bi201034z
10.1021/jm9014857
ContentType Journal Article
Copyright Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley.
Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley
Copyright_xml – notice: Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley.
– notice: Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2022.826617
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals - May need to register for free articles
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
PubMed


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_98cb02dc3d834271aee89357a5bf59d2
PMC8988139
35402225
10_3389_fonc_2022_826617
Genre Journal Article
GrantInformation_xml – fundername: NEI NIH HHS
  grantid: R01 EY031939
– fundername: NHLBI NIH HHS
  grantid: U01 HL143403
– fundername: NCI NIH HHS
  grantid: R01 CA211098
– fundername: NCI NIH HHS
  grantid: P30 CA082709
– fundername: NCI NIH HHS
  grantid: R01 CA167291
– fundername: NHLBI NIH HHS
  grantid: R01 HL140961
– fundername: NCI NIH HHS
  grantid: R01 CA231267
– fundername: NCI NIH HHS
  grantid: R01 CA254110
– fundername: NCI NIH HHS
  grantid: R01 CA205166
– fundername: ;
– fundername: ;
  grantid: NF180045
– fundername: ;
  grantid: HL140961, HL143403
– fundername: ;
  grantid: EY031939
– fundername: ;
  grantid: CA167291, CA254110, CA205166, CA231267, CA211098, P30CA08270
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c462t-c0d16a11ce45674a58a18ed0daee8b352d242ef49e9886c14a4a44a3827b2f6e3
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:32:30 EDT 2025
Thu Aug 21 18:12:49 EDT 2025
Fri Jul 11 07:34:41 EDT 2025
Thu Jan 02 22:24:00 EST 2025
Thu Apr 24 22:56:34 EDT 2025
Tue Jul 01 02:46:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords redox signaling
Ape1
pancreatic ductal adenocarcinoma (PDAC)
PRDX1
STAT3
transcriptional factors
DNA repair
relA
Language English
License Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-c0d16a11ce45674a58a18ed0daee8b352d242ef49e9886c14a4a44a3827b2f6e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors share senior authorship
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Edited by: Michael Weinfeld, University of Alberta, Canada
Reviewed by: Dindial Ramotar, Hamad bin Khalifa University, Qatar; Bruce Demple, Stony Brook University, United States; Lynn Harrison, Louisiana State University Health Shreveport, United States
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2022.826617
PMID 35402225
PQID 2649256293
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_98cb02dc3d834271aee89357a5bf59d2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8988139
proquest_miscellaneous_2649256293
pubmed_primary_35402225
crossref_primary_10_3389_fonc_2022_826617
crossref_citationtrail_10_3389_fonc_2022_826617
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-24
PublicationDateYYYYMMDD 2022-03-24
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-24
  day: 24
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Gujral (B9) 2017; 114
Wu (B7) 2021; 6
Luo (B34) 2008; 10
Fishel (B40) 2014; 290
Gong (B10) 2014; 20
Silke (B4) 2021; 13
Hu (B3) 2021; 42
Grivennikov (B8) 2010; 21
Pramanik (B6) 2018; 19
Zhang (B39) 2013; 52
Gampala (B14) 2020
Brennan (B44) 2020; 39
Shah (B24) 2017; 11
Wilson (B26) 2010; 67
Roebuck (B42) 1999; 19
Fujioka (B30) 2004; 24
Cai (B45) 2018; 23
Caston (B28) 2021; 25
Curtis Heisel (B11) 2021; 2
Cesaratto (B17) 2013; 8
Oliveira (B19) 2021; 9
Kelley (B36) 2011; 14
Mendonca (B32) 2018; 1
Wang (B43) 2018; 9
Sahakian (B46) 2020; 27
Ischenko (B2) 2021; 12
Conradt (B23) 2013; 132
Jedinak (B33) 2011; 31
Algül (B22) 2007; 117
Gampala (B25) 2021; 40
Caston (B13) 2021; 26
Rai (B27) 2012; 55
Gampala (B20) 2021; 124
Kelley (B12) 2012; 5
McIlwain (B18) 2018; 9
Ling (B5) 2012; 21
Fishel (B29) 2015; 290
Nassour (B15) 2016; 6
Sarantis (B1) 2020; 12
Pan (B31) 2008; 14
Luo (B38) 2012; 51
Ando (B16) 2008; 36
Sardar Pasha (B37) 2018; 367
Fishel (B41) 2019; 18
Nyland (B35) 2010; 53
Lesina (B21) 2016; 126
Hartman (B47) 2021; 22
References_xml – volume: 40
  start-page: 251
  year: 2021
  ident: B25
  article-title: Ref-1 Redox Activity Alters Cancer Cell Metabolism in Pancreatic Cancer: Exploiting This Novel Finding as a Potential Target
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-02046-x
– volume: 24
  year: 2004
  ident: B30
  article-title: NF-kappaB and AP-1 Connection: Mechanism of NF-kappaB-Dependent Regulation of AP-1 Activity
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.24.17.7806-7819.2004
– volume: 22
  start-page: 10279
  year: 2021
  ident: B47
  article-title: Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms221910279
– volume: 290
  year: 2014
  ident: B40
  article-title: Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.621995
– volume: 26
  year: 2021
  ident: B13
  article-title: The Multifunctional APE1 DNA Repair–Redox Signaling Protein as a Drug Target in Human Disease
  publication-title: Drug Discovery Today
  doi: 10.1016/j.drudis.2020.10.015
– volume: 11
  year: 2017
  ident: B24
  article-title: APE1/Ref-1 Knockdown in Pancreatic Ductal Adenocarcinoma - Characterizing Gene Expression Changes and Identifying Novel Pathways Using Single-Cell RNA Sequencing
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12138
– volume: 27
  start-page: 388
  year: 2020
  ident: B46
  article-title: Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis
  publication-title: Inflammatory Bowel Dis
  doi: 10.1093/ibd/izaa161
– volume: 67
  year: 2010
  ident: B26
  article-title: Small Molecule Inhibitors of DNA Repair Nuclease Activities of APE1
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-010-0488-2
– volume: 124
  year: 2021
  ident: B20
  article-title: Exploring Transcriptional Regulators Ref-1 and STAT3 as Therapeutic Targets in Malignant Peripheral Nerve Sheath Tumours
  publication-title: Br J Cancer
  doi: 10.1038/s41416-021-01270-8
– volume: 39
  start-page: 184
  year: 2020
  ident: B44
  article-title: Selective Antagonism of Cjun for Cancer Therapy
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-020-01686-9
– volume: 19
  start-page: 3890
  year: 2018
  ident: B6
  article-title: Advancement of NF-kappaB Signaling Pathway: A Novel Target in Pancreatic Cancer
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19123890
– volume: 9
  year: 2018
  ident: B18
  article-title: APE1/Ref-1 Redox-Specific Inhibition Decreases Survivin Protein Levels and Induces Cell Cycle Arrest in Prostate Cancer Cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.23493
– volume: 6
  start-page: 29389
  year: 2016
  ident: B15
  article-title: Peroxiredoxin 1 Interacts With and Blocks the Redox Factor APE1 From Activating Interleukin-8 Expression
  publication-title: Sci Rep
  doi: 10.1038/srep29389
– volume: 55
  year: 2012
  ident: B27
  article-title: Synthesis, Biological Evaluation, and Structure-Activity Relationships of a Novel Class of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors
  publication-title: J Med Chem
  doi: 10.1021/jm201537d
– volume: 8
  start-page: e70909
  year: 2013
  ident: B17
  article-title: Specific Inhibition of the Redox Activity of Ape1/Ref-1 by E3330 Blocks Tnf-Alpha-Induced Activation of IL-8 Production in Liver Cancer Cell Lines
  publication-title: PloS One
  doi: 10.1371/journal.pone.0070909
– volume: 126
  year: 2016
  ident: B21
  article-title: RelA Regulates CXCL1/CXCR2-Dependent Oncogene-Induced Senescence in Murine Kras-Driven Pancreatic Carcinogenesis
  publication-title: J Clin Invest
  doi: 10.1172/JCI86477
– volume: 290
  year: 2015
  ident: B29
  article-title: Apurinic/apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.621995
– volume: 117
  year: 2007
  ident: B22
  article-title: Pancreas-Specific RelA/p65 Truncation Increases Susceptibility of Acini to Inflammation-Associated Cell Death Following Cerulein Pancreatitis
  publication-title: J Clin Invest
  doi: 10.1172/JCI29882
– volume: 13
  start-page: 4510
  year: 2021
  ident: B4
  article-title: NF-κB and Pancreatic Cancer; Chapter and Verse
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13184510
– volume: 5
  start-page: 36
  year: 2012
  ident: B12
  article-title: APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
  publication-title: Curr Mol Pharmacol
  doi: 10.2174/1874467211205010036
– volume: 31
  year: 2011
  ident: B33
  article-title: Apurinic/Apyrimidinic Endonuclease 1 Regulates Inflammatory Response in Macrophages
  publication-title: Anticancer Res
– volume: 367
  year: 2018
  ident: B37
  article-title: Ref-1/APE1 Inhibition With Novel Small Molecules Blocks Ocular Neovascularization
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.118.248088
– volume: 6
  start-page: 218
  year: 2021
  ident: B7
  article-title: Signaling Pathways in Cancer-Associated Fibroblasts and Targeted Therapy for Cancer
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00641-0
– volume: 114
  year: 2017
  ident: B9
  article-title: Hippo Pathway Mediates Resistance to Cytotoxic Drugs
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1703096114
– volume: 9
  year: 2021
  ident: B19
  article-title: Chemical Inhibition of Apurinic-Apyrimidinic Endonuclease 1 Redox and DNA Repair Functions Affects the Inflammatory Response via Different But Overlapping Mechanisms
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2021.731588
– volume: 52
  year: 2013
  ident: B39
  article-title: Inhibition of Apurinic/Apyrimidinic Endonuclease I's Redox Activity Revisited
  publication-title: Biochemistry
  doi: 10.1021/bi400179m
– volume: 21
  year: 2010
  ident: B8
  article-title: Dangerous Liaisons: STAT3 and NF-kappaB Collaboration and Crosstalk in Cancer
  publication-title: Cytokine Growth Factor Rev
  doi: 10.1016/j.cytogfr.2009.11.005
– volume: 23
  start-page: 833
  year: 2018
  ident: B45
  article-title: Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2018.10.013
– volume: 42
  year: 2021
  ident: B3
  article-title: Mutations in Key Driver Genes of Pancreatic Cancer: Molecularly Targeted Therapies and Other Clinical Implications
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/s41401-020-00584-2
– volume: 20
  year: 2014
  ident: B10
  article-title: Combined Targeting of STAT3/NF-κb/COX-2/EP4 for Effective Management of Pancreatic Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-1664
– volume: 12
  start-page: 1482
  year: 2021
  ident: B2
  article-title: KRAS Drives Immune Evasion in a Genetic Model of Pancreatic Cancer
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-21736-w
– volume: 21
  year: 2012
  ident: B5
  article-title: KrasG12D-Induced IKK2/beta/NF-kappaB Activation by IL-1alpha and P62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.12.006
– volume: 19
  year: 1999
  ident: B42
  article-title: Regulation of Interleukin-8 Gene Expression
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/107999099313866
– volume: 2
  year: 2021
  ident: B11
  article-title: APE1/Ref-1 as a Novel Target for Retinal Diseases
  publication-title: J Cell Signaling
  doi: 10.33696/Signaling.2.044
– volume: 25
  start-page: 784
  year: 2021
  ident: B28
  article-title: Combined Inhibition of Ref-1 and STAT3 Leads to Synergistic Tumour Inhibition in Multiple Cancers Using 3D and In Vivo Tumour Co-Culture Models
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.16132
– volume: 18
  year: 2019
  ident: B41
  article-title: Anti-Tumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-18-1166
– volume: 14
  year: 2008
  ident: B31
  article-title: Nuclear factor-kappaB P65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1539
– volume: 132
  year: 2013
  ident: B23
  article-title: Mdm2 Inhibitors Synergize With Topoisomerase II Inhibitors to Induce P53-Independent Pancreatic Cancer Cell Death
  publication-title: Int J Cancer
  doi: 10.1002/ijc.27916
– volume: 14
  year: 2011
  ident: B36
  article-title: Functional Analysis of New and Novel Analogs of E3330 That Block the Redox Signaling Activity of the Multifunctional AP Endonuclease/Redox Signaling Enzyme APE1/Ref-1
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3410
– volume: 10
  year: 2008
  ident: B34
  article-title: Role of the Multifunctional DNA Repair and Redox Signaling Protein Ape1/Ref-1 in Cancer and Endothelial Cells: Small-Molecule Inhibition of the Redox Function of Ape1
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2008.2120
– volume: 12
  year: 2020
  ident: B1
  article-title: Pancreatic Ductal Adenocarcinoma: Treatment Hurdles, Tumor Microenvironment and Immunotherapy
  publication-title: World J Gastrointest Oncol
  doi: 10.4251/wjgo.v12.i2.173
– start-page: 286
  volume-title: DNA Damage, DNA Repair and Disease
  year: 2020
  ident: B14
  article-title: Basic, Translational and Clinical Relevance of the DNA Repair and Redox Signaling Protein APE1 in Human Diseases
  doi: 10.1039/9781839162541-00286
– volume: 36
  year: 2008
  ident: B16
  article-title: A New APE1/Ref-1-Dependent Pathway Leading to Reduction of NF-κb and AP-1, and Activation of Their DNA-Binding Activity
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkn416
– volume: 9
  year: 2018
  ident: B43
  article-title: AP-1 Confers Resistance to Anti-Cancer Therapy by Activating XIAP
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.23897
– volume: 1
  year: 2018
  ident: B32
  article-title: Determining If Double Gene Knockdown of P65 and PDK2 Increases Cytotoxicity and Radiation Sensitivity of Pancreatic Cancer Cells
  publication-title: Proc IMPRS
  doi: 10.18060/22794
– volume: 51
  start-page: 695
  year: 2012
  ident: B38
  article-title: Characterization of the Redox Activity and Disulfide Bond Formation in Apurinic/Apyrimidinic Endonuclease
  publication-title: Biochemistry
  doi: 10.1021/bi201034z
– volume: 53
  year: 2010
  ident: B35
  article-title: Design and Synthesis of Novel Quinone Inhibitors Targeted to the Redox Function of Apurinic/Apyrimidinic Endonuclease 1/Redox Enhancing Factor-1 (Ape1/Ref-1)
  publication-title: J Med Chem
  doi: 10.1021/jm9014857
SSID ssj0000650103
Score 2.321698
Snippet Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 826617
SubjectTerms Ape1
DNA repair
Oncology
pancreatic ductal adenocarcinoma (PDAC)
redox signaling
relA
transcriptional factors
SummonAdditionalLinks – databaseName: Directory of Open Access Journals - May need to register for free articles
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6btOH6jQSw_urmVZlo_bzYa0sGHZJpCb0WOcGBY5rB3oH-v_64ztLLultJfik2WNJTRjzzfW-BvGPlapVc4Lotl3IpZZXsSFT1XsptjqnMpFRZ8Glufq7FJ-u8qu9kp9UU7YQA88LNyk0M5OhXep16kUeWIA0MVmuclslRW-f_uiz9sLpoZ3cEYFDIZ9SYzCiknVBGIsFOKzJp-UH_ihnq7_Txjz91TJPd9z-oQ9HkEjnw2TfcoeQHjGHi7HbfHn7OcaNjP-teUm8EVLvxOhVfGLPsmbIyrli3BDvBrhms9hs6HMU74ekmOh5V3DEQXyk_MZNt6aejtZQxUneOKbH_x7fU1YHUVXROlQBxzEk3TXp-7xFWzRa1mErH7_5iRKJdgbRJ9t3XKUWzZ3LfDVyWzed2xfsMvTxcX8LB7rMcROKtGh_nyiTJI4QNSVS5Npk2jwU086sYjkPPp7qGQBhdbKJdLgIU2qRW5FpSB9yY5CE-A145nxCUhvphZ7KK9t7jDQNNakkJhUyohN7rVTupGsnGpmbEoMWkifJemzJH2Wgz4j9mkncTsQdfyl7xdS-K4fUWz3DWh45Wh45b8ML2If7s2lxEeS9llMAFzJEjFmgUgSgVTEXg3msxuKPrNRiB2x_MCwDuZyeCXUNz3tt8ZVRbx-_D8m_4Y9ovWgZDoh37KjbnsH7xBddfZ9_yD9AmFDJUU
  priority: 102
  providerName: Directory of Open Access Journals
Title RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostasis in Mouse PDAC Cells
URI https://www.ncbi.nlm.nih.gov/pubmed/35402225
https://www.proquest.com/docview/2649256293
https://pubmed.ncbi.nlm.nih.gov/PMC8988139
https://doaj.org/article/98cb02dc3d834271aee89357a5bf59d2
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF7aFEIupe-qj7CFXnpQ7F2tpNWhFNdxmhYcjBuDb2JfcgxCSiUF0h_W_9cZSXbjYnooBoFXO5K9M6v5Znf0DSHvs0BHxnKk2TfcF2Gc-IkNIt8ModWYKOYZLg1ML6Lzhfi2DJd_Xo_uB7DeG9phPalFlZ_c_vj5CSb8R4w4wd8OsrJAMkLOTyS6m_g-eQB-KcZ6BtMe7HfP5RCLGnR7lXsFj8ghLoNgCLTjplo2_30Q9O9Myjuu6ewRedhjSjrqjOAxueeKJ-Rw2u-aPyW_5i4f0a81VQWd1Pi2ERgdvWxzwCmAVjoprpB2o1jRsctzTEyl8y531tW0KSmARHp6MYLGa7WuBnOX-Qy-2PKWfl-vEMqD6AwZH9YF3MSidNNm9tGZq8CpaUC09u7FURQrtJcATut1TUFuWt7Ujs5OR-O2Y_2MLM4ml-Nzvy_X4BsR8QbUa1mkGDMOQFksVCgVk84OrXJOagB6FuCAy0TiEikjw4SCj1CB5LHmWeSC5-SgKAv3ktBQWeaEVUMNPSIrdWwgDlVaBY6pQAiPDDbaSU3PZY4lNfIUYhpUbYqqTVG1aadaj3zYSlx3PB7_6PsZFb7thwzcbUNZrdJ-QqeJNHrIrQmsDASPGf7JJAhjFeosTCz3yLuNuaQwY3EbRhUORjIFCJoA0ASc5ZEXnflsb7UxP4_EO4a181t2zxTrq5YVXMKoApx_9d-Sr8kRDgIm2HHxhhw01Y17C4ir0cftSgUcvyzZcTupfgPlSS9F
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=RelA+Is+an+Essential+Target+for+Enhancing+Cellular+Responses+to+the+DNA+Repair%2FRef-1+Redox+Signaling+Protein+and+Restoring+Perturbated+Cellular+Redox+Homeostasis+in+Mouse+PDAC+Cells&rft.jtitle=Frontiers+in+oncology&rft.au=Mijit%2C+Mahmut&rft.au=Wireman%2C+Randall&rft.au=Armstrong%2C+Lee&rft.au=Gampala%2C+Silpa&rft.date=2022-03-24&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=12&rft_id=info:doi/10.3389%2Ffonc.2022.826617&rft_id=info%3Apmid%2F35402225&rft.externalDocID=PMC8988139
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon